EditorialKommentar
Switching Between Intravenous and Oral P2Y12 Inhibition
JACC: Cardiovascular Interventions · 2023
DOI: 10.1016/j.jcin.2022.11.014 ↗Kurz gefasst
Editorial in der Zeitschrift JACC: Cardiovascular Interventions, 2023. Verfasst von Usman Baber. Beteiligte Einrichtung: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. Electronic address: usman-baber@ouhsc.edu. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Acute Coronary Syndrome. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Percutaneous Coronary InterventionAcute Coronary SyndromeHumansTreatment OutcomePlatelet Aggregation InhibitorsTicagrelorAdministration, IntravenousPurinergic P2Y Receptor AntagonistsAdenosine MonophosphateReceptors, Purinergic P2Y12
Stichwörter der Autor:innen
acute coronary syndromecangrelorplatelet inhibition
Substanzen
Platelet Aggregation InhibitorsTicagrelorPurinergic P2Y Receptor AntagonistsAdenosine MonophosphateReceptors, Purinergic P2Y12
Autor:innen und Institutionen
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. Electronic address: usman-baber@ouhsc.edu.
Zitieren
APA
Baber, U. (2023). Switching Between Intravenous and Oral P2Y12 Inhibition. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2022.11.014
Vancouver
Baber U. Switching Between Intravenous and Oral P2Y12 Inhibition. JACC: Cardiovascular Interventions. 2023. doi:10.1016/j.jcin.2022.11.014
BibTeX
@article{Baber2023,
author = {Baber, Usman},
title = {Switching Between Intravenous and Oral P2Y12 Inhibition},
journal = {JACC: Cardiovascular Interventions},
year = {2023},
doi = {10.1016/j.jcin.2022.11.014}
}
EUVIMED